Trial · NCT03068468
Adverse events792
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 792
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Placebo (Placebo Controlled Period) | 15 | 162 | |
| other | Constipation | Gastrointestinal disorders | BIIB092 2000 mg (Placebo Controlled Period) | 36 | 324 | |
| other | Constipation | Gastrointestinal disorders | BIIB092 Late Start (Open-label Extension Period) | 4 | 137 | |
| other | Constipation | Gastrointestinal disorders | BIIB092 Early Start (Open-label Extension Period) | 16 | 279 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Placebo Controlled Period) | 9 | 162 | |
| other | Diarrhoea | Gastrointestinal disorders | BIIB092 2000 mg (Placebo Controlled Period) | 23 | 324 | |
| other | Diarrhoea | Gastrointestinal disorders | BIIB092 Late Start (Open-label Extension Period) | 4 | 137 | |
| other | Diarrhoea | Gastrointestinal disorders | BIIB092 Early Start (Open-label Extension Period) | 9 | 279 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (Placebo Controlled Period) | 14 | 162 | |
| other | Nasopharyngitis | Infections and infestations | BIIB092 2000 mg (Placebo Controlled Period) | 28 | 324 | |
| other | Nasopharyngitis | Infections and infestations | BIIB092 Late Start (Open-label Extension Period) | 6 | 137 | |
| other | Nasopharyngitis | Infections and infestations | BIIB092 Early Start (Open-label Extension Period) | 16 | 279 | |
| other | Urinary tract infection | Infections and infestations | Placebo (Placebo Controlled Period) | 31 | 162 | |
| other | Urinary tract infection | Infections and infestations | BIIB092 2000 mg (Placebo Controlled Period) | 56 | 324 | |
| other | Urinary tract infection | Infections and infestations | BIIB092 Late Start (Open-label Extension Period) | 15 | 137 | |
| other | Urinary tract infection | Infections and infestations | BIIB092 Early Start (Open-label Extension Period) | 36 | 279 | |
| other | Contusion | Injury, poisoning and procedural complications | Placebo (Placebo Controlled Period) | 24 | 162 | |
| other | Contusion | Injury, poisoning and procedural complications | BIIB092 2000 mg (Placebo Controlled Period) | 41 | 324 | |
| other | Contusion | Injury, poisoning and procedural complications | BIIB092 Late Start (Open-label Extension Period) | 15 | 137 | |
| other | Contusion | Injury, poisoning and procedural complications | BIIB092 Early Start (Open-label Extension Period) | 24 | 279 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03068468/events